Literature DB >> 11885998

Long-term renal function after treatment for malignant germ-cell tumours.

S D Fosså1, N Aass, M Winderen, O P Börmer, D R Olsen.   

Abstract

OBJECTIVE: To evaluate prospectively renal function in patients with malignant germ-cell tumours (MGCTs) >10 years after retroperitoneal lymph node dissection alone (RPLND), radiotherapy alone (RAD) or different schedules of cisplatin-based chemotherapy with or without surgery/radiotherapy (CHEM). PATIENTS AND METHODS: In 85 patients, three groups were identified: RPLND, 14; RAD, 18; CHEM, 53, with subdivision of the latter group according to the cumulative cisplatin dose or the additional use of radiotherapy. Renal function was determined by 131Iodine Hippuran clearance or 99m DTPA glomerular filtration rate, and was assessed before treatment and four times during 14 years of follow-up. A value of <70% of the upper limit of the normal range identified impaired renal function.
RESULTS: Twenty-five patients displayed long-term impaired renal function, 23 of them from the RAD or CHEM group. In the RAD group, renal function decreased by 8%, whereas a 14% reduction of renal function was observed in the CHEM group. In the CHEM group the cumulative dose of cisplatin, and in the RAD group the age at treatment, were associated with impairment of renal function. Combining all patients, age at treatment and the type of treatment were associated with impaired renal function.
CONCLUSIONS: In 20-30% of the patients with germ-cell tumour, standard radiotherapy and chemotherapy strategies are followed by long-term subclinical impaired renal function. These findings support current intentions to avoid overtreatment with these treatment modalities.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11885998     DOI: 10.1093/annonc/mdf048

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  26 in total

Review 1.  Advances in the treatment of testicular cancer.

Authors:  Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; Michael Bamberg; Jörg Thomas Hartmann
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Current Concepts in Management of Stage I NSGCT.

Authors:  Puneet Ahluwalia; Gagan Gautam
Journal:  Indian J Surg Oncol       Date:  2016-12-17

Review 3.  Testicular cancer survivorship: research strategies and recommendations.

Authors:  Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa
Journal:  J Natl Cancer Inst       Date:  2010-06-28       Impact factor: 13.506

Review 4.  Robotic Primary RPLND for Stage I Testicular Cancer: a Review of Indications and Outcomes.

Authors:  Heather J Chalfin; Wesley Ludwig; Phillip M Pierorazio; Mohamad E Allaf
Journal:  Curr Urol Rep       Date:  2016-05       Impact factor: 3.092

Review 5.  [Long-term toxicity after therapy for testicular cancer with special focus on sexual disorders].

Authors:  J Oldenburg; S D Fosså
Journal:  Urologe A       Date:  2009-04       Impact factor: 0.639

Review 6.  Testicular cancer: a prototypic tumor of young adults.

Authors:  Brandon Hayes-Lattin; Craig R Nichols
Journal:  Semin Oncol       Date:  2009-10       Impact factor: 4.929

7.  Three-Dimensional Morphology by Multiphoton Microscopy with Clearing in a Model of Cisplatin-Induced CKD.

Authors:  Richard Torres; Heino Velazquez; John J Chang; Michael J Levene; Gilbert Moeckel; Gary V Desir; Robert Safirstein
Journal:  J Am Soc Nephrol       Date:  2015-08-24       Impact factor: 10.121

8.  Characterizing the Morbidity of Postchemotherapy Retroperitoneal Lymph Node Dissection for Testis Cancer in a National Cohort of Privately Insured Patients.

Authors:  Liam C Macleod; Saneal Rajanahally; Jasmir G Nayak; Brodie A Parent; Jorge D Ramos; George R Schade; Sarah K Holt; Atreya Dash; John L Gore; Daniel W Lin
Journal:  Urology       Date:  2016-01-21       Impact factor: 2.649

Review 9.  [Delayed effects of oncological therapy].

Authors:  H Biersack; G Brabant
Journal:  Internist (Berl)       Date:  2013-10       Impact factor: 0.743

10.  Current update of management of clinical stage I non seminomatous germ cell tumors of testis.

Authors:  T B Yuvaraja
Journal:  Indian J Surg Oncol       Date:  2012-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.